Carisma Therapeutics Inc. (CARM) - Total Liabilities
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has total liabilities worth $7.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Carisma Therapeutics Inc. growing its equity to track the company's year-over-year net asset growth rate.
Carisma Therapeutics Inc. - Total Liabilities Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Carisma Therapeutics Inc. (CARM) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Carisma Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Carisma Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sabien Technology Group Plc
LSE:SNT
|
UK | GBX727.00K |
|
Ordinary Fully Paid Deferred Settlement
AU:HRZDB
|
Australia | AU$110.94 Million |
|
GenIP PLC
LSE:GNIP
|
UK | GBX145.66K |
|
Fibra Mty S.A.P.I. de C.V.
MX:FMTY14
|
Mexico | MX$122.93 Billion |
|
Sorted Group Holdings Plc
LSE:SORT
|
UK | GBX6.50 Million |
|
SCG PACKAGING -FGN- BA 1
F:5Y7A
|
Germany | €87.08 Billion |
|
AdCapital AG
F:ADC
|
Germany | €67.13 Million |
|
musicMagpie PLC
LSE:MMAG
|
UK | GBX28.30 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Carisma Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CARM market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Carisma Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual total liabilities of Carisma Therapeutics Inc. from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $58.37 Million | -7.39% |
| 2023-12-31 | $63.02 Million | -70.66% |
| 2022-12-31 | $214.82 Million | +52.48% |
| 2021-12-31 | $140.89 Million | -28.73% |
| 2020-12-31 | $197.68 Million | +40.13% |
| 2019-12-31 | $141.06 Million | +109.44% |
| 2018-12-31 | $67.35 Million | +18.03% |
| 2017-12-31 | $57.06 Million | -12.77% |
| 2016-12-31 | $65.42 Million | +265.86% |
| 2015-12-31 | $17.88 Million | -1.61% |
| 2014-12-31 | $18.17 Million | +104.41% |
| 2013-12-31 | $8.89 Million | +136.21% |
| 2012-12-31 | $3.76 Million | +33.85% |
| 2011-12-31 | $2.81 Million | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more